We analyzed patients who had acute ischemic stroke treated with intravenous tissue plasminogen activator within 4.5 hours of onset from the Get With The Guidelines-Stroke US national program. tissue plasminogen activator treatment improves ischemic stroke outcome, but aspects of the time-benefit relationship still not well delineated are: (1) the degree of additional benefit accrued with treatment in the first 60 minutes after onset, and (2) the shape of the time-benefit curve through 4.5 hours.
2 From Department of Neurology, Chonnam National University Hospital, Gwangju, Korea (J.-T.K.) Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles (G.C.F.) Hotchkiss Brain Institute, University of Calgary, Alberta, Canada (E.E.S.) Department of Epidemiology and Biostatistics, Michigan State University, East Lansing (M.J.R.) Department of Neurology, University of Texas Health Science Center, Houston (D.D.N.) Clinical Innovation and Research Institute, Memorial Hermann Hospital, Houston, TX (J.C.G.) Outcome Research and Assessment Group, Duke Clinical Research Institute, Durham, NC (M.V.G.-S., A.F.H., E.D.P.) Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston (L.H.S.) and Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles (J.L.S.).1 From Department of Neurology, Chonnam National University Hospital, Gwangju, Korea (J.-T.K.) Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles (G.C.F.) Hotchkiss Brain Institute, University of Calgary, Alberta, Canada (E.E.S.) Department of Epidemiology and Biostatistics, Michigan State University, East Lansing (M.J.R.) Department of Neurology, University of Texas Health Science Center, Houston (D.D.N.) Clinical Innovation and Research Institute, Memorial Hermann Hospital, Houston, TX (J.C.G.) Outcome Research and Assessment Group, Duke Clinical Research Institute, Durham, NC (M.V.G.-S., A.F.H., E.D.P.) Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston (L.H.S.) and Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles (J.L.S.). 1 From Department of Neurology, Chonnam National University Hospital, Gwangju, Korea (J.-T.K.) Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles (G.C.F.) Hotchkiss Brain Institute, University of Calgary, Alberta, Canada (E.E.S.) Department of Epidemiology and Biostatistics, Michigan State University, East Lansing (M.J.R.) Department of Neurology, University of Texas Health Science Center, Houston (D.D.N.) Clinical Innovation and Research Institute, Memorial Hermann Hospital, Houston, TX (J.C.G.) Outcome Research and Assessment Group, Duke Clinical Research Institute, Durham, NC (M.V.G.-S., A.F.H., E.D.P.) Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston (L.H.S.) and Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles (J.L.S.).
0 kommentar(er)
